Closing the data loop in AI-driven drug discovery
Article summary
Quick briefing — cleaned from the original RSS feed
Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs…
1Key Takeaways
- Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage.
- Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law.
- Today, bringing a new drug to market takes an average of 10-15 years and costs….
2AIWedia Score
9.9/10
Must-read — high impact for AI builders
Based on source trust, recency, category impact, and story depth.
3Why it matters
Research breakthroughs often arrive in products months later—early signals matter for strategy. MIT Tech Review reports that drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage.
Explore related
Browse toolsRelated tools
Research news
Explore curated research tools on AIWedia — compare, rank, and launch from our directory.
Full story on MIT Tech Review
Read full articleHeadlines aggregated via RSS for discovery on AIWedia. Original content © MIT Tech Review. We link to the source and do not republish full articles.